U.S. Markets close in 23 mins.

Amgen Inc. (AMGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
187.395-0.775 (-0.412%)
As of 3:37PM EDT. Market open.
People also watch
BIIBGILDCELGMRKBMY
Full screen
Previous Close188.170
Open188.320
Bid187.110 x 400
Ask187.130 x 200
Day's Range186.870 - 188.960
52 Week Range133.640 - 191.100
Volume1,435,720
Avg. Volume2,796,482
Market Cap136.74B
Beta1.79
PE Ratio (TTM)17.07
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield4.60 (2.47%)
Ex-Dividend Date2017-08-15
1y Target EstN/A
Trade prices are not sourced from all markets
  • Pfizer Sues J&J, Accuses it of Preventing Inflectra Uptake
    Zacks5 hours ago

    Pfizer Sues J&J, Accuses it of Preventing Inflectra Uptake

    Pfizer (PFE) filed a lawsuit in a U.S. district court alleging that J&J is resorting to anticompetitive practices to prevent uptake of Inflectra.

  • See what the IHS Markit Score report has to say about Amgen Inc.
    Markityesterday

    See what the IHS Markit Score report has to say about Amgen Inc.

    Amgen Inc NASDAQ/NGS:AMGN

  • American City Business Journals2 days ago

    Amgen challenge to Genentech $6 billion cancer drug OK'd by FDA

    A "biosimilar" version of the cancer drug Avastin — Genentech Inc.'s best-selling oncology treatment — was approved Thursday by the Food and Drug Administration, potentially crimping the $6 billion franchise of the South San Francisco-based drug maker's Swiss parent. The drug, which Amgen Inc. (AMGN) and partner Allergan plc (AGN) will sell as Mvasi, also is known by the scientific name bevacizumab. The drug regulator's approval allows it to be used to treat metastatic colorectal cancer and types of lung, kidney, cervical and brain cancers.